{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:49:13Z","timestamp":1769888953593,"version":"3.49.0"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1055\/a-2500-0927","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T23:53:08Z","timestamp":1745365988000},"page":"562-569","source":"Crossref","is-referenced-by-count":2,"title":["Behandlung des metastasierten Melanoms \u2013 Update 2025"],"prefix":"10.1055","volume":"150","author":[{"given":"Georg","family":"Lodde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea Jessica","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"D Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref3","first-page":"45","article-title":"Longer survival from melanoma in Germany: A registry-based time series study","volume":"121","author":"N Eisemann","year":"2024","journal-title":"Dtsch Arztebl Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"JD Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"C Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/a-2231-7157","article-title":"Behandlung des metastasierten Melanoms","volume":"45","author":"G Lodde","year":"2024","journal-title":"TumorDiagn u Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"HA Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"JCO2401124","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","author":"HA Tawbi","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","volume":"35","author":"GV Long","year":"2024","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s43018-023-00610-2","article-title":"Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma","volume":"4","author":"R V\u00e1raljai","year":"2023","journal-title":"Nat Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115119","article-title":"Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients","volume":"214","author":"C Robert","year":"2025","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"S733","DOI":"10.1016\/j.annonc.2024.08.1175","article-title":"1107P \u2013 Characteristics and quality of life of nine-year survivors from 312 patients with metastatic melanoma treated with pembrolizumab","volume":"35","author":"JC Hassel","year":"2024","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"J Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"J Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"9559","DOI":"10.1200\/JCO.2024.42.16_suppl.9559","article-title":"Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti\u2013PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study","volume":"42","author":"AM Arance","year":"2024","journal-title":"JCO"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/j.cell.2024.03.039","article-title":"IGSF8 is an innate immune checkpoint and cancer immunotherapy target","volume":"187","author":"Y Li","year":"2024","journal-title":"Cell"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"S716","DOI":"10.1016\/j.annonc.2024.08.1149","article-title":"1081MO \u2013 Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma","volume":"35","author":"PA Ascierto","year":"2024","journal-title":"Ann Oncol"},{"issue":"S 16","key":"ref19","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1200\/JCO.2024.42.16_suppl.9517","article-title":"Efficacy and safety of RP1 combined with nivolumab in patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial","volume":"42","author":"MKK Wong","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"AA Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"JA Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"MW Rohaan","year":"2022","journal-title":"N Engl J Med"},{"issue":"S 01","key":"ref23","doi-asserted-by":"publisher","first-page":"100589","DOI":"10.1016\/iotech\/iotech100589","article-title":"Domingo-Musibay, Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study.  (Abstract 119O, presented at ESMO 2023)","volume":"20","author":"CM Wermke","year":"2023","journal-title":"Annals of Oncology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e008640","DOI":"10.1136\/jitc-2023-008640","article-title":"Biomarkers for response to TIL therapy: a comprehensive review","volume":"12","author":"V Albarr\u00e1n Fern\u00e1ndez","year":"2024","journal-title":"J Immunother Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e008659","DOI":"10.1136\/jitc-2023-008659","article-title":"Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers","volume":"12","author":"T Gargett","year":"2024","journal-title":"J Immunother Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03418-4","article-title":"Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial","author":"JSW Borgers","year":"2025","journal-title":"Nat Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"JC Hassel","year":"2023","journal-title":"N Engl J Med"},{"issue":"S 16","key":"ref30","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2024.42.16_suppl.9507","article-title":"Phase 1 safety and efficacy of IMC-F106C, a PRAME\u00d7 CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)","volume":"42","author":"O Hamid","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"L Heinzerling","year":"2019","journal-title":"ESMO Open"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114073","article-title":"COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma","volume":"204","author":"D Schadendorf","year":"2024","journal-title":"Eur J Cancer"},{"issue":"S 16","key":"ref34","doi-asserted-by":"publisher","first-page":"9540","DOI":"10.1200\/JCO.22.01763","article-title":"EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600\u2013mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-\/MEK inhibition","volume":"40","author":"M Weichenthal","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial \u2013 ECOG-ACRIN EA6134","volume":"41","author":"MB Atkins","year":"2023","journal-title":"J Clin Oncol"},{"issue":"S 02","key":"ref36","first-page":"S653","article-title":"1083MO \u2013 Brain metastases and survival evaluation in the SECOMBIT trial","volume":"34","author":"M Mandal\u00e0","year":"2023","journal-title":"Ann Oncol"},{"issue":"S 02","key":"ref37","doi-asserted-by":"crossref","first-page":"S1235","DOI":"10.1016\/j.annonc.2024.08.2286","article-title":"LBA45 \u2013 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial","volume":"35","author":"D Schadendorf","year":"2024","journal-title":"Ann Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 validated in two independent cohorts: implications for adjuvant treatment","volume":"40","author":"C Garbe","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejca.2019.05.020","article-title":"Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325\/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma","volume":"116","author":"AMM Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"issue":"S 02","key":"ref40","doi-asserted-by":"crossref","first-page":"S713","DOI":"10.1016\/j.annonc.2024.08.1145","article-title":"1077MO \u2013 Adjuvant nivolumab v placebo in stage IIB\/C melanoma: 3-year results from CheckMate 76K","volume":"35","author":"GV Long","year":"2024","journal-title":"Ann Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 Study","volume":"42","author":"JJ Luke","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"391","author":"GV Long","year":"2024","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial","volume":"211","author":"AMM Eggermont","year":"2024","journal-title":"Eur J Cancer"},{"issue":"S 02","key":"ref44","doi-asserted-by":"crossref","first-page":"S656","DOI":"10.1016\/j.annonc.2023.09.2223","article-title":"1089P \u2013 Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III\/IV melanoma: 7-y results from CheckMate 238","volume":"34","author":"P Ascierto","year":"2023","journal-title":"Ann Oncol"},{"issue":"S 02","key":"ref45","doi-asserted-by":"crossref","first-page":"S715","DOI":"10.1016\/j.annonc.2024.08.1147","article-title":"1079MO \u2013 Survival before and after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study","volume":"35","author":"H Helgadottir","year":"2024","journal-title":"Ann Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"SP Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"CU Blank","year":"2024","journal-title":"N Engl J Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2500-0927.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T23:53:21Z","timestamp":1745366001000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2500-0927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2500-0927","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}